Abstract: The present invention provides a composition comprising or consisting of components (a) (i) at least one mono-alkanoyl glycerol ester, wherein alkanoyl is selected from C4 to C21 alkanoyl, preferably from octanoyl and decanoyl; and (b) (i) at least one compound selected from cholesterol, phosphatidyl cholines and phosphatidyl glycerols, wherein the acyl moieties of the phosphatidyl moieties are independently selected from C6 to C21 alkanoyl and C6 to C21 alkenoyl.
Abstract: Compositions and methods are provided for mucosal delivery of peptides. The compositions include a stably hydrated peptide active agent complexed with a crown compound and/or a counter ion solubilized in a non-aqueous hydrophobic vehicle at a pH different from the pI of the peptide active agent. The methods include administering to a subject an effective amount of a composition of the disclosure. Other aspects include methods for the manufacture of the compositions of the disclosure. Also provided are compositions and kits that find use in practicing embodiments of the disclosure. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
Abstract: The present invention provides a composition comprising or consisting of components (a) (i) at least one mono-alkanoyl glycerol ester, wherein alkanoyl is selected from C4 to C21 alkanoyl, preferably from octanoyl and decanoyl; and (b) (i) at least one compound selected from cholesterol, phosphatidyl cholines and phosphatidyl glycerols, wherein the acyl moieties of the phosphatidyl moieties are independently selected from C6 to C21 alkanoyl and C6 to C21 alkenoyl.
Abstract: This invention relates to A crown ether of formula (I) wherein m is 4, 5, 6, 7, or 8 and i is, independently for each occurrence, 1 or 2; each occurrence of R1 and R2 is independently selected from hydrogen; linear or branched and substituted or unsubstituted C1 to C10 alkyl, alkenyl and alkinyl; and substituted or unsubstituted aryl with up to 10 ring atoms; or R1 and R2 together form an oxo group; at least one occurrence in the crown ether of R1, R2 and the carbon to which R1 and R2 are attached, said carbon being bound directly to an ether oxygen of formula (I), form together a group of formula (II) wherein L is a linker which is absent or selected from a covalent bond and (CR5R6)n, each occurrence of R5 and R6 being independently selected from hydrogen; linear or branched and substituted or unsubstituted C1 to C10 alkyl, alkenyl and alkinyl; and substituted or unsubstituted aryl with up to 10 ring atoms, n being 1, 2 or 3; X and Y, independently from each other, are selected from O and S; Z, inde
Type:
Grant
Filed:
November 25, 2010
Date of Patent:
January 7, 2014
Assignee:
Arisgen SA
Inventors:
Paolo Botti, Sylvie Tchertchian, Doriane Theurillat
Abstract: This invention relates to A crown ether of formula (I) wherein m is 4, 5, 6, 7, or 8 and i is, independently for each occurrence, 1 or 2; each occurrence of R1 and R2 is independently selected from hydrogen; linear or branched and substituted or unsubstituted C1 to C10 alkyl, alkenyl and alkinyl; and substituted or unsubstituted aryl with up to 10 ring atoms; or R1 and R2 together form an oxo group; at least one occurrence in the crown ether of R1, R2 and the carbon to which R1 and R2 are attached, said carbon being bound directly to an ether oxygen of formula (I), form together a group of formula (II) wherein L is a linker which is absent or selected from a covalent bond and (CR5R6)n, each occurrence of R5 and R6 being independently selected from hydrogen; linear or branched and substituted or unsubstituted C1 to C10 alkyl, alkenyl and alkinyl; and substituted or unsubstituted aryl with up to 10 ring atoms, n being 1, 2 or 3; X and Y, independently from each other, are selected from O and S; Z, indep
Type:
Application
Filed:
November 25, 2010
Publication date:
November 29, 2012
Applicant:
ARISGEN SA
Inventors:
Paolo Botti, Sylvie Tchertchian, Doriane Theurillat
Abstract: Compositions and methods are provided for mucosal delivery of peptides. The compositions include a stably hydrated peptide active agent complexed with a crown compound and/or a counter ion solubilized in a non-aqueous hydrophobic vehicle at a pH different from the pI of the peptide active agent. The methods include administering to a subject an effective amount of a composition of the disclosure. Other aspects include methods for the manufacture of the compositions of the disclosure. Also provided are compositions and kits that find use in practicing embodiments of the disclosure. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.